Project Grant R21AI193189
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $243K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the Scripps Research Institute $897,277 on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct structural and functional research on monkeypox virus entry mechanisms and neutralizing antibody responses. The work integrates antibody isolation from mpox convalescents, vaccine recipients, and a human antibody phage...
- The National Institute of Allergy and Infectious Diseases awarded Cincinnati Children's Hospital Medical Center $808,811 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate a pan-filovirus virus-like particle vaccine. The research evaluates a trivalent filovirus VLP vaccine candidate expressing glycoproteins from Ebola virus, Sudan virus, and Marburg virus. Prior studies in non-human primate models demonstrated that bivalent VLPs...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $160,448 on March 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and validate mutations in orthopoxviruses that confer resistance to acyclic phosphonates, characterize the biochemical mechanisms of inhibition by and resistance to these compounds, and evaluate combination therapies to prevent resistance emergence. The research responds to the 2022 global mpox...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $458,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 4, 2025, with a completion date of August 31, 2027. The project, titled "A VP4-Based Pseudovirus Nanoparticle Rotavirus Vaccine for Oral Immunization," focuses on developing a non-replicating rotavirus...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $264,633 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize antivirals against poxviruses. The funded work advances preclinical development of modified carbocyclic nucleoside analogs targeting monkeypox virus (MPXV) and vaccinia virus (VACV). The research team identified a lead compound demonstrating potency of 187 nanomolar...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $235,500 to the University of California Irvine on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R21AI196970. The award funds research on the molecular architecture of the vaccinia virus factory, with emphasis on characterizing protein interactions at the molecular level during virion morphogenesis. The research...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $840,018 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define mechanisms by which A35-specific monoclonal antibodies confer protection against monkeypox virus and to characterize qualitative differences in A35-targeted antibody responses elicited by infection versus vaccination. The research addresses inadequacies in current...
- Federal Project Grant Award Summary New York University School of Medicine received a $466,125 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2027. The award funds research to elucidate the molecular mechanisms of orthopoxvirus entry, specifically examining the critical initial interactions between viral and human cellular proteins...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded The Washington University $765,798 on September 3, 2026, to develop a mucosal H5 influenza virus vaccine under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop a single-dose mucosal vaccine using a chimpanzee adenovirus vectored platform to confer robust protection against high-dose H5N1 challenge and transmission in pre-clinical...